文献速递类风湿关节炎其他结缔组织病

Filgotinib类风湿关节炎与溃疡性结肠炎临床开发项目中的主要不良心血管、血栓栓塞及恶性肿瘤事件

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.
PubMed 文献 · RMD Open · 2025-03-04

该整合分析汇总了filgotinib 100 mg或200 mg每日一次治疗类风湿关节炎(RA)和溃疡性结肠炎(UC)的所有II期和III期试验数据,暴露量分别超过12500患者年和2800患者年。总体人群中关注的不良事件(MACE、VTE、恶性肿瘤)发生率低,但≥65岁患者中MACE(RA患者)、恶性肿瘤(排除非黑色素瘤皮肤癌)及非黑色素瘤皮肤癌(RA或UC患者)的发生率呈数值升高。结论认为总体安全性数据与既往分析一致,≥65岁患者不良事件发生率数值升高,需进一步数据评估心血管危险因素的影响,未观察到一致的filgotinib剂量效应。

要点

  • 总体人群中MACE、VTE和恶性肿瘤发生率低,与既往总体安全性分析一致。
  • ≥65岁RA患者中MACE(100 mg与200 mg发生率相同)、恶性肿瘤及非黑色素瘤皮肤癌发生率数值升高。
  • ≥65岁RA患者接受200 mg时VTE暴露调整发生率(95%CI)为0.3(0.1, 0.8)/100患者年;≥65岁UC患者无VTE事件。

核心结论

  • 数据与既往总体安全性分析一致,显示总体研究人群中关注的不良事件发生率低。
  • ≥65岁患者中关注的不良事件发生率数值升高;需进一步数据评估心血管危险因素的影响。
  • 总体而言,本分析中filgotinib对关注的不良事件无一致的剂量效应。

研究设计与样本

  • 整合分析至今所有研究filgotinib 100 mg或200 mg每日一次治疗RA和UC的II期和III期试验数据。
  • 分析代表filgotinib在RA中超过12500患者年、在UC中超过2800患者年的暴露量。

主要发现

  • 整合分析人群中关注的不良事件发生率低。
  • ≥65岁患者中发生率数值 modest 升高,包括RA患者的MACE、RA或UC患者的恶性肿瘤(排除非黑色素瘤皮肤癌)及非黑色素瘤皮肤癌。
  • VTE罕见;≥65岁RA患者接受filgotinib 200 mg时VTE暴露调整发生率(95%CI)为0.3(0.1, 0.8)/100患者年;≥65岁UC患者无VTE事件。
  • ≥65岁RA患者中,MACE发生率在filgotinib 100 mg与200 mg之间相同;恶性肿瘤和非黑色素瘤皮肤癌发生率200 mg数值高于100 mg。

局限性

  • 需进一步数据评估心血管危险因素的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse cardiovascular events (MACE), venous thromboembolism (VTE) and malignancies. METHODS: Data were integrated from all phase II and III trials that have investigated filgotinib 100 mg or 200 mg once daily in RA and UC to date. RESULTS: Analyses represent >12 500 (RA) and >2800 (UC) patient-years of exposure (PYE) to filgotinib. Incidences of AEI in the integrated analysis population were low. Modest numerical increases in incidence rates occurred in patients aged ≥65 years, including MACE (patients with RA), and malignancies (excluding non-melanoma skin cancer (NMSC)) and NMSC (patients with RA or UC). VTE was rare; in patients with RA aged ≥65 years receiving filgotinib 200 mg, exposure-adjusted incidence rate (95% CI) for VTE was 0.3 (0.1, 0.8)/100 PYE; no VTE events occurred in patients with UC aged ≥65 years. In patients with RA aged ≥65 years, MACE incidence rates were identical between filgotinib 100 mg and 200 mg; rates of malignancies and NMSC were numerically higher with 200 mg compared with 100 mg. CONCLUSIONS: Data are consistent with previous overall safety analyses demonstrating low rates of AEI in the overall study population. Numerically increased rates of AEI occurred in patients aged ≥65 years; further data are needed to assess the effect of CV risk factors. Overall, in this analysis, there was no consistent filgotinib dose effect on AEI.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mariette X, Borchmann S, Aspeslagh S, et al. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025. PMID: 40037922. doi:10.1136/rmdopen-2024-005033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。